FDA's MedWatch Safety Alerts: October 2013

FDA warns consumers about a hepatitis health advisory linked to supplement use, and undeclared ingredients found in a dietary supplement and more.
Source: FDA Consumer Updates - Category: Consumer Health News Source Type: news

Related Links:

Publication date: Available online 10 October 2020Source: Journal of Clinical and Experimental HepatologyAuthor(s): Pramod Kumar, Anand Kulkarni, Mithun Sharma, Padaki Nagaraja Rao
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
Authors: Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K Abstract BACKGROUND: Although clinical use of sofosbuvir plus ribavirin has been approved for patients infected with genotype 2 hepatitis C virus, patients ≥ 75-years-old have not been included in previous clinical trials. AIM: To evaluate the real-world safety and efficacy of sofosbuvir plus ribavirin for elderly patients (≥ 75-years-old) compared to nonelderly patients, we conducted a post-marketing prospective cohort study. METHODS: We treated 265 patients with ge...
Source: World Journal of Hepatology - Category: Gastroenterology Tags: World J Hepatol Source Type: research
CONCLUSION: DAAs are effective and safe in the treatment of recurrent HCV infection in LT recipients with history of HCC. Relapse to pre- and post-LT DAA therapy is associated with post-transplantation HCC recurrence. PMID: 33033569 [PubMed]
Source: World Journal of Hepatology - Category: Gastroenterology Tags: World J Hepatol Source Type: research
We report the rare case of a patient co-existing NS and DLBCL. DLBCL might be pathogenesis of NS; the findings are supported by the presence of MN, an underlying malignancy (DLBCL), and the lack of anti-PLA2R antibodies. Although further investigation is warranted, our case suggests that DLBCL is a possible cause of secondary MN. PMID: 33028760 [PubMed - in process]
Source: The Tohoku Journal of Experimental Medicine - Category: Research Authors: Tags: Tohoku J Exp Med Source Type: research
In conclusion, our multidisciplinary approach to prevent de novo hepatitis B is considered useful. PMID: 33028756 [PubMed - in process]
Source: The Tohoku Journal of Experimental Medicine - Category: Research Authors: Tags: Tohoku J Exp Med Source Type: research
Publication date: 10–16 October 2020Source: The Lancet, Volume 396, Issue 10257Author(s): Talha Burki
Source: The Lancet - Category: General Medicine Source Type: research
ConclusionHepatitis B virus infection is a global health problem affecting about 257 million people worldwide. In Nepal, there are few reports on the molecular and phylogenetic analysis of this virus. In this study, we report the circulation of seropositive occult hepatitis as well as CD-recombinant genotype in Nepalese population.
Source: Indian Journal of Gastroenterology - Category: Gastroenterology Source Type: research
ConclusionsThe study confirmed significant changes in the HCV genotypes partition with G3 genotype rapidly increasing in both countries, with possible impact on the WHO eradication initiative and treatment selection.
Source: International Journal of Public Health - Category: International Medicine & Public Health Source Type: research
Harvey J. Alter, Michael Houghton, and Charles M. Rice awarded for their work
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
Publication date: Available online 9 October 2020Source: Arab Journal of GastroenterologyAuthor(s): Shereen M. Galal, Shaban M. Soror, Omima Hussien, Ehab F. Moustafa, Sahar M Hassany
Source: Arab Journal of Gastroenterology - Category: Gastroenterology Source Type: research
More News: Health | Hepatitis | Nutrition